Skip to main content
Equibles

Andrew Allen

Board Member

Adaptimmune Therapeutics PLC (ADAPY)
Adaptimmune Therapeutics PLC (ADAPY)

Equibles does not estimate personal net worth.

Get an email with a short summary when Adaptimmune Therapeutics PLC publishes a filing, an earnings call transcript or a press release.

Get ADAPY alerts

About Andrew Allen

Andrew Allen is recorded as Board Member at Adaptimmune Therapeutics PLC (ADAPY). The newest filing on record that lists Andrew Allen as Board Member at Adaptimmune Therapeutics PLC (ADAPY) is dated April 25, 2025. Adaptimmune Therapeutics PLC reported in an 8-K filed June 1, 2023 that Andrew Allen was appointed member of the Board's Remuneration Committee, effective June 1, 2023. Adaptimmune Therapeutics PLC reported in an 8-K filed June 1, 2023 that Andrew Allen was appointed non-executive director, effective June 1, 2023. Adaptimmune Therapeutics PLC is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Adaptimmune Therapeutics PLC includes Adrian Rawcliffe (CEO and Board Member), David M. Mott (Chairman), Christopher Hill (CFO) and 7 others.

“The board of directors ("Board") of Adaptimmune Therapeutics plc ("Company") is pleased that you have agreed to join the Board as a non-executive director and to serve as a member of the Board's Remuneration Committee with effect from 1 June 2023.”
Adaptimmune Therapeutics PLC Form 8-K, filed June 1, 2023 · Read the filing
“The board of directors ("Board") of Adaptimmune Therapeutics plc ("Company") is pleased that you have agreed to join the Board as a non-executive director and to serve as a member of the Board's Remuneration Committee with effect from 1 June 2023.”
Adaptimmune Therapeutics PLC Form 8-K, filed June 1, 2023 · Read the filing

Affiliation history

Company network

Leadership on record at Adaptimmune Therapeutics PLC

Recent activity